For the third quarter of 2026, Acadia Healthcare is projected to report consensus revenue of $877.76 million and earnings of $0.46 per share, with shares currently trading at $29.96 compared to an analyst price target of $33.79.
Investors are intensely focused on same-facility admissions growth to validate if recent massive bed expansions are translating into improved utilization and cash flow.
The company is working through significant legal headwinds, including ongoing DOJ and SEC investigations into patient care and billing practices. Despite these challenges, management recently tightened its operational focus, aiming to realize $200 million in incremental EBITDA from its new facility cohort by 2027.